Experientia

, Volume 44, Issue 2, pp 137–141

Platelet monoamine oxidase B: Use and misuse

  • M. B. H. Youdim
Multi-author Review The Platelet in Pathophysiological Research

DOI: 10.1007/BF01952197

Cite this article as:
Youdim, M.B.H. Experientia (1988) 44: 137. doi:10.1007/BF01952197

Summary

The human platelet in addition to having serotonin (5-HT) receptors, uptake carriers (receptor) and transmitter storage vesicles, primarily possesses mitochondrial monoamine oxidase (MAO) type B. Similar to the major form of MAO in the human brain, this enzyme actively oxidizes A-B and B substrates (tyramine, dopamine, phenylethylamine) as well as the novel secondary amine anticonvulsant, milacemide and dopaminergic neurotoxin, MPTP. 5-HT oxidation is hardly affected by the platelet enzyme and MAO inhibitors have no net effect on its accumulation. MAO-B is selectively inhibited by 1-deprenyl and thus the platelet enzyme may be useful to monitor the anti-Parkinson activity of such drugs, as related to their ability to inhibit brain MAO-B. The oxidation of the anticonvulsant, milacemide, to glycine in vitro and in vivo by MAO-B, may herald new prospects for the development of inert prodrugs capable of being metabolized to neuroactive substances by MAO-B. The plasma levels of their metabolites may be an index of MAO-B activity found in the platelet and brain.

Key words

Monoamine oxidase A and BserotoninphenylethylaminemilacemideParkinson's diseaseepilepsyanticonvulsantplateletclorgyline and deprenyl

Copyright information

© Birkhäuser Verlag 1988

Authors and Affiliations

  • M. B. H. Youdim
    • 1
    • 2
  1. 1.Rappaport Family Research Institute, Faculty of MedicineTechnionHaifa(Israel)
  2. 2.Department of Pharmacology, Faculty of MedicineTechnionHaifa(Israel)